Clinical study of digital biomarker platform in degenerative neurological diseases

Cumulus Neuroscience has announced the start of two validation trials – CNS-101 and CNS-102 – supported by a group of leading global pharma companies and Innovate UK. The studies will investigate the potential benefits of Cumulus’ integrated physiological and digital biomarker platform in quantifying cognitive decline over time in patients with various neurological conditions.

The studies will investigate the benefits of the platform in patients with dementia, across Alzheimer’s Disorder (AD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).

read more